bovnews1d
BTIG Research Just Downgraded Fiverr International Ltd (FVRR) Stock—What Does This Mean for Investors?
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
Hosted on MSN2h
BTIG Downgrades Palo Alto Networks (PANW)
Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...
BTIG Sticks to Their Buy Rating for Globus Medical (GMED)
In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...
Cipher Mining (NASDAQ:CIFR) Given Overweight Rating at Cantor Fitzgerald
Cipher Mining (NASDAQ:CIFR – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They ...
bovnews19h
Beyond Air Inc (XAIR) Stock Settles at $0.41: What’s Contributing to This Price Point?
BTIG Research has recently reduced Beyond Air Inc (XAIR) stock to Neutral rating, as announced on June 25, 2024, according to Finviz. Earlier, on July 28, 2023, Piper Sandler had initiated the stock ...
Penumbra (PEN) Receives a Buy from BTIG
BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $270.00. The ...
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Average PT from Analysts
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...
Denali Therapeutics price target lowered to $32 from $35 at BTIG
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
Carvana under fire: Research report claims turnaround is a "mirage"
Short seller Hindenburg Research accused Carvana of accounting manipulation and unstable loans. The company denies the ...
Stock rally faces resistance: BTIG's Krinsky
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
Staar Surgical price target lowered to $39 from $49 at BTIG
BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of ...
Hosted on MSN1d
BTIG Initiates Coverage of Hims & Hers Health (HIMS) with Buy Recommendation
Fintel reports that on January 7, 2025, BTIG initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy recommendation.